Advantages of liposomal delivery systems for anthracyclines

Seminars in Oncology

Volumn 31, Issue SUPPL. 13, 2004, Pages 5-15

  Allen, Theresa M ^a,c   Martin, Francis J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALZA CORPORATION   (United States)

^c X AB T6G 2H7 Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMPHOTERICIN B; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARDIOLIPIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; LIPOSOME; LURTOTECAN; MACROGOL; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; STEALTH; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

ALOPECIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CYTOTOXICITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYDROPHILICITY; IC 50; KAPOSI SARCOMA; LIPID BILAYER; MYCOSIS; NONHUMAN; OPSONIZATION; PH MEASUREMENT; PHAGOCYTE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; STOMATITIS;

EID: 11144310022     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.08.001     Document Type: Article

References (101)

1. T.M. Allen, P.R. Cullis Drug delivery systems entering the mainstream Science 303 2004 1818 1822
2. A.D. Bangham, R.W. Horne Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J Mol Biol 8 1964 660 668
3. R. Janknegt Liposomal formulations of cytotoxic drugs Support Care Cancer 4 1996 298 304
4. K.J. Hwang Liposome pharmacokinetics K.F. Hwang M.J. Ostro Liposomes From Biophysics to Therapeutics 1987 Marcel Dekker New York, NY 109 156
5. S.K. Huang, K.D. Lee, K. Hong Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice Cancer Res 52 1992 5135 5143
6. G. Poste Liposome targeting in vivo Problems and opportunities Biol Cell 47 1983 19 38
7. A. Chonn, P.R. Cullis Ganglioside GM1 and hydrophilic polymers increase liposome circulation times by inhibiting the association of blood proteins J Liposome Res 2 1992 397 410
8. D. Papahadjopoulos, T.M. Allen, A. Gabizon Sterically stabilized liposomes improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci U S A 88 1991 11460 11464
9. G. Berry, M. Billingham, E. Alderman The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin Ann Oncol 9 1998 711 716
10. D.W. Northfelt, F.J. Martin, P. Working Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J Clin Pharmacol 36 1996 55 63
11. M.A. Amantea, R.A. Bowden, A. Forrest Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants Antimicrob Agents Chemother 39 1995 2042 2047
12. T.M. Allen, C. Hansen Pharmacokinetics of stealth versus conventional liposomes Effect of dose Biochim Biophys Acta 1068 1991 133 141
13. D.D. Lasic, F.J. Martin, A. Gabizon Sterically stabilized liposomes A hypothesis on the molecular origin of the extended circulation times Biochim Biophys Acta 1070 1991 187 192
14. T.M. Allen Toxicity of drug carriers to the mononuclear phagocyte system Adv Drug Deliv Rev 2 1988 55 67
15. F. Martin Pegylated liposomal doxorubicin Scientific rationale and preclinical pharmacology Oncology 11 suppl 11 1997 11 19
16. A. Rahman, J. Treat, J.K. Roh A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin J Clin Oncol 8 1990 1093 1100
17. A. Gabizon, T. Peretz, A. Sulkes Systemic administration of doxorubicin-containing liposomes in cancer patients A phase I study Eur J Cancer Clin Oncol 25 1989 1795 1803
18. G. Delgado, R.K. Potkul, J.A. Treat A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer Am J Obstet Gynecol 160 1989 812 817 discussion 817-819
19. D.J. Vaughn, J.A. Treat, P. Drobins A phase I study of a new liposome encapsulated doxorubicin (LED) formulation in advanced malignancies Proc Am Soc Clin Oncol 18 1999 231a (abstr 892)
20. M. Fishman, L. Strauss, J. Pei Liposome-encapsulated mitoxantrone (LEM) Pharmacokinetic and phase I studies Proc Am Soc Clin Oncol 21 2002 84b (abstr 2147)
21. P.C. Gokhale, J. Pei, C. Zhang Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone Anticancer Res 21 2001 3313 3321
22. J.L. Steinberg, M. Fishman, P. Lorusso Pharmacokinetics and safety of liposome encapsulated mitoxantrone (LEM) in patients with advanced cancer A phase I study Proc Am Soc Clin Oncol 22 2003 240 (abstr 961)
23. X. Li, D.J. Hirsh, D. Cabral-Lilly Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient Biochim Biophys Acta 1415 1998 23 40
24. L.D. Mayer, M.B. Bally, P.R. Cullis Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim Biophys Acta 857 1986 123 126
25. C.E. Swenson, J. Freitag, A.S. Janoff The liposome company Lipid-based pharmaceuticals in clinical development D. Lasic D. Papahadjopoulos Medical Applications of Liposomes 1998 Elsevier New York, NY 689 701
26. L. Embree, K. Gelmon, A. Tolcher Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection Cancer Chemother Pharmacol 41 1998 347 352
27. K.A. Gelmon, A. Tolcher, A.R. Diab Phase I study of liposomal vincristine J Clin Oncol 17 1999 697 705
28. D.F. Kehrer, A.M. Bos, J. Verweij Phase I and pharmacologic study of liposomal lurtotecan, NX 211 Urinary excretion predicts hematologic toxicity J Clin Oncol 20 2002 1222 1231
29. P. Tardi, E. Choice, D. Masin Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res 60 2000 3389 3393
30. J.A. Treat, S. Zrada, S. Kesslehelm A phase I trial in advanced malignancies with liposome encapsulated paclitaxel (LEP) Proc Am Soc Clin Oncol 18 1999 230a (abstr 888)
31. J. Treat, N. Damjanov, C. Huang Liposomal-encapsulated chemotherapy Preliminary results of a phase I study of a novel liposomal paclitaxel Oncology (Huntingt) 15 2001 44 48
32. M.N. Fishman, P. Lorusso, E. Kraut Phase I study of liposome encapsulated SN38 (LE-SN38) in patients with advanced cancer Proc Am Soc Clin Oncol 22 2003 150 (abstr 600)
33. AmBisome (amphotericin B liposome for injection) prescribing information 2000 Fujisawa Healthcare, Inc Deerfield, IL
34. T.M. Allen The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system Adv Drug Deliv Rev 13 1994 285 309
35. T.M. Allen, J.M. Everest Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats J Pharmacol Exp Ther 226 1983 539 544
36. D. Goren, A. Gabizon, Y. Barenholz The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior Biochim Biophys Acta 1029 1990 285 294
37. R.T. Proffitt, L.E. Williams, C.A. Presant Liposomal blockade of the reticuloendothelial system Improved tumor imaging with small unilamellar vesicles Science 220 1983 502 505
38. M.C. Woodle, D.D. Lasic Sterically stabilized liposomes Biochim Biophys Acta 1113 1992 171 199
39. DaunoXome (daunorubicin citrate liposome injection) prescribing information 2002 Gilead Sciences, Inc San Dimas, CA
40. R.M. Abra, M.E. Bosworth, C.A. Hunt Liposome disposition in vivo effects of pre-dosing with liposomes Res Commun Chem Pathol Pharmacol 29 1980 349 360
41. T.M. Allen, A. Chonn Large unilamellar liposomes with low uptake into the reticuloendothelial system FEBS Lett 223 1987 42 46
42. A. Gabizon, R. Shiota, D. Papahadjopoulos Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times J Natl Cancer Inst 81 1989 1484 1488
43. T.M. Allen, C. Hansen, J. Rutledge Liposomes with prolonged circulation times Factors affecting uptake by reticuloendothelial and other tissues Biochim Biophys Acta 981 1989 27 35
44. A.L. Klibanov, K. Maruyama, V.P. Torchilin Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett 268 1990 235 237
45. G. Blume, G. Cevc Liposomes for the sustained drug release in vivo Biochim Biophys Acta 1029 1990 91 97
46. P.K. Working, M.S. Newman, S.K. Huang Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (DOXIL) J Liposome Res 4 1994 667 687
47. V.P. Torchilin, V.S. Trubetskoy, K.R. Whiteman New synthetic amphiphilic polymers for steric protection of liposomes in vivo J Pharm Sci 84 1995 1049 1053
48. V.P. Torchilin Polymer-coated long-circulating microparticulate pharmaceuticals J Microencapsul 15 1998 1 19
49. S. Zalipsky, C.B. Hansen, J.M. Oaks Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes J Pharm Sci 85 1996 133 137
50. Doxil (doxorubicin HCl liposome injection) prescribing information 2001 Ortho Biotech Products Bridgewater, NJ
51. G. Haran, R. Cohen, L.K. Bar Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim Biophys Acta 1151 1993 201 215
52. J.W. Cowens, P.J. Creaven, W.R. Greco Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes) Cancer Res 53 1993 2796 2802
53. T.M. Allen Liposomal drug formulations. Rationale for development and what we can expect for the future Drugs 56 1998 747 756
54. S.K. Hobbs, W.L. Monsky, F. Yuan Regulation of transport pathways in tumor vessels Role of tumor type and microenvironment Proc Natl Acad Sci U S A 95 1998 4607 4612
55. R.K. Jain Transport of molecules across tumor vasculature Cancer Metastasis Rev 6 1987 559 593
56. H.F. Dvorak, J.A. Nagy, J.T. Dvorak Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules Am J Pathol 133 1988 95 109
57. F. Yuan, M. Leunig, S.K. Huang Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res 54 1994 3352 3356
58. J. Vaage, E. Barbera-Guillem, R. Abra Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1994 1478 1484
59. K.J. Harrington, S. Mohammadtaghi, P.S. Uster Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin Cancer Res 7 2001 243 254
60. S. Stewart, K.J. Harrington The biodistribution and pharmacokinetics of Stealth liposomes in patients with solid tumors Oncology 11 suppl 11 1997 33 37
61. D.D. Lasic Liposomes From Physics to Applications 1993 Elsevier Science New York, NY
62. M.A. Amantea, A. Forrest, D.W. Northfelt Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma Clin Pharmacol Ther 61 1997 301 311
63. F.A. Tavassoli, C.B. Cook, J.P. Pestaner A comparison of two commercially available in vitro chemosensitivity assays Oncology 52 1995 413 418
64. R.W. Holloway, R.S. Mehta, N.J. Finkler Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol 87 2002 8 16
65. G.H. Eltabbakh, M.S. Piver, R.E. Hempling Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer Gynecol Oncol 70 1998 392 397
66. D.M. Vail, M.A. Amantea, G.T. Colbern Pegylated liposomal doxorubicin Proof of principle using preclinical animal models and pharmacokinetic studies Semin Oncol 31 suppl 13 2004 16 35
67. A.T. Horowitz, Y. Barenholz, A.A. Gabizon In vitro cytotoxicity of liposome-encapsulated doxorubicin Dependence on liposome composition and drug release Biochim Biophys Acta 1109 1992 203 209
68. D. Schrag, H.S. Garewal, H.J. Burstein American Society of Clinical Oncology Technology Assessment Chemotherapy sensitivity and resistance assays J Clin Oncol 22 2004 3631 3638
69. C.A. Hunter, T.F. Dolan, G.H. Coombs Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis J Pharm Pharmacol 40 1988 161 165
70. K.M. Wasan, G. Lopez-Berestein The past, present, and future uses of liposomes in treating infectious diseases Immunopharmacol Immunotoxicol 17 1995 1 15
71. J.J. Killion, I.J. Fidler Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators Pharmacol Ther 78 1998 141 154
72. I.A. Bakker-Woudenberg, A.F. Lokerse, M.T. ten Kate Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue Biochim Biophys Acta 1138 1992 318 326
73. E.T. Dams, W.J. Oyen, O.C. Boerman Technetium-99m-labeled liposomes to image experimental colitis in rabbits comparison with technetium-99m-HMPAO- granulocytes and technetium-99m-HYNIC-IgG J Nucl Med 39 1998 2172 2178
74. E.T. Dams, W.J. Oyen, O.C. Boerman 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation clinical evaluation J Nucl Med 41 2000 622 630
75. M.T. Ercan, L. Kostakoglu Radiopharmaceuticals for the visualization of infectious and inflammatory lesions Curr Pharm Des 6 2000 1159 1177
76. P. Laverman, O.C. Boerman, W.J. Oyen Liposomes for scintigraphic detection of infection and inflammation Adv Drug Deliv Rev 37 1999 225 235
77. W.J. Oyen, O.C. Boerman, G. Storm Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes J Nucl Med 37 1996 1392 1397
78. R.M. Schiffelers, I.A. Bakker-Woudenberg, G. Storm Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia Dependence on circulation kinetics and presence of poly(ethylene)glycol coating Biochim Biophys Acta 1468 2000 253 261
79. R.M. Schiffelers, G. Storm, M.T. ten Kate Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin Antimicrob Agents Chemother 45 2001 464 470
80. G. Pagnan, D.D. Stuart, F. Pastorino Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes Antitumor effects J Natl Cancer Inst 92 2000 253 261
81. D.D. Stuart, G.Y. Kao, T.M. Allen A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 Cancer Gene Ther 7 2000 466 475
82. I. Ahmad, M. Longenecker, J. Samuel Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice Cancer Res 53 1993 1484 1488
83. D.E. Lopes de Menezes, L.M. Pilarski, T.M. Allen In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma Cancer Res 58 1998 3320 3330
84. T.M. Allen, E.H. Moase Therapeutic opportunities for targeted liposomal drug delivery Adv Drug Deliv Rev 21 1996 117 133
85. T. Ishida, D.L. Iden, T.M. Allen A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs FEBS Lett 460 1999 129 133
86. E.H. Moase, W. Qi, T. Ishida Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer Biochim Biophys Acta 1510 2001 43 55
87. D. Goren, A.T. Horowitz, S. Zalipsky Targeting of stealth liposomes to erbB-2 (Her/2) receptor In vitro and in vivo studies Br J Cancer 74 1996 1749 1756
88. W.D. Beecken, A. Fernandez, A.M. Joussen Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice J Natl Cancer Inst 93 2001 382 387
89. F. Pastorino, C. Brignole, D. Marimpietri Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy Cancer Res 63 2003 7400 7409
90. C.L. Shapiro, T. Ervin, L. Welles Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group J Clin Oncol 17 1999 1435 1441
91. L.D. Mayer, M.B. Bally, M.J. Hope Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential Biochim Biophys Acta 816 1985 294 302
92. A. Gabizon, H. Shmeeda, Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin Review of animal and human studies Clin Pharmacokinet 42 2003 419 436
93. B.A. Conley, M.J. Egorin, M.Y. Whitacre Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin Cancer Chemother Pharmacol 33 1993 107 112
94. D.S. Alberts, D.J. Garcia Safety aspects of pegylated liposomal doxorubicin in patients with cancer Drugs 54 suppl 4 1997 30 35
95. D.S. Alberts, D.J. Garcia A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies Oncology 11 suppl 10 1997 54 62
96. P.K. Working, M.S. Newman, T. Sullivan Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes J Pharmacol Exp Ther 289 1999 1128 1133
97. M. Amantea, M.S. Newman, T.M. Sullivan Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs Hum Exp Toxicol 18 1999 17 26
98. A.J. Coukell, C.M. Spencer Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma Drugs 53 1997 520 538
99. L. Harris, G. Batist, R. Belt Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36
100. G. Batist, G. Ramakrishnan, C.S. Rao Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 2001 1444 1454
101. G. Batist, J. Barton, P. Chaikin Myocet (liposome-encapsulated doxorubicin citrate) A new approach in breast cancer therapy Expert Opin Pharmacother 3 2002 1739 1751